AmeriCares, Baxter team up to deliver IV solutions to prevent cholera outbreak in Haiti

AmeriCares and Baxter International Inc. have teamed to deliver additional lifesaving intravenous (IV) solutions to Haiti as part of their ongoing effort to stem the cholera outbreak.  AmeriCares has been working around the clock to distribute IV solutions, oral rehydration salts, antibiotics, hand sanitizers and other critical aid since the outbreak was reported in October.  As a leading manufacturer of products used in the delivery of fluids and drugs to patients, Baxter's donations have been an integral part of the response. AmeriCares airlifted an additional 50,000 pounds of aid over the weekend which will be used to re-supply depleted stocks at cholera treatment centers and hospitals in Port-au-Prince.

Baxter has donated IV rehydration solutions and IV sets to administer the solutions that will help to bring lifesaving aid to at least 25,000 patients suffering in Haiti.  Baxter has teamed with AmeriCares for nearly 25 years to share its innovative products and treatments with people in need throughout the world and has an ongoing commitment to work with AmeriCares to meet the needs of Haiti. Recently, Baxter has pre-positioned medicines and solutions in the AmeriCares warehouse, ready to be mobilized in the event of an emergency such as this cholera outbreak.

"It is estimated that more than 300,000 people will be hospitalized with cholera in the next six to eight months. This donation from Baxter is essential to getting ahead of this deadly, but treatable, disease," President and CEO of AmeriCares, Curt Welling, said. "AmeriCares has worked closely with Baxter since 1987, responding to health care needs around the world.  They have been generous with their products and understand the value of providing lifesaving aid to the world's most vulnerable populations."

By working together, AmeriCares and Baxter will not only help treat patients currently suffering from cholera, but will pre-position critical aid so it is ready to be delivered directly into the hands of health care professionals treating people newly diagnosed. In one month alone, 15,000 Haitians have been hospitalized for cholera. For those with acute cholera, it requires eight liters of IV solution to rehydrate and save their life. Without proper rehydration, patients can die within 10-12 hours if not treated right away.

SOURCE AmeriCares

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2010, December 21). AmeriCares, Baxter team up to deliver IV solutions to prevent cholera outbreak in Haiti. News-Medical. Retrieved on February 04, 2023 from https://www.news-medical.net/news/20101221/AmeriCares-Baxter-team-up-to-deliver-IV-solutions-to-prevent-cholera-outbreak-in-Haiti.aspx.

  • MLA

    Baxter International Inc.. "AmeriCares, Baxter team up to deliver IV solutions to prevent cholera outbreak in Haiti". News-Medical. 04 February 2023. <https://www.news-medical.net/news/20101221/AmeriCares-Baxter-team-up-to-deliver-IV-solutions-to-prevent-cholera-outbreak-in-Haiti.aspx>.

  • Chicago

    Baxter International Inc.. "AmeriCares, Baxter team up to deliver IV solutions to prevent cholera outbreak in Haiti". News-Medical. https://www.news-medical.net/news/20101221/AmeriCares-Baxter-team-up-to-deliver-IV-solutions-to-prevent-cholera-outbreak-in-Haiti.aspx. (accessed February 04, 2023).

  • Harvard

    Baxter International Inc.. 2010. AmeriCares, Baxter team up to deliver IV solutions to prevent cholera outbreak in Haiti. News-Medical, viewed 04 February 2023, https://www.news-medical.net/news/20101221/AmeriCares-Baxter-team-up-to-deliver-IV-solutions-to-prevent-cholera-outbreak-in-Haiti.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer